Management of severe bio-radiation dermatitis induced by radiotherapy and cetuximab in patients with head and neck cancer: emphasizing the role of calcium alginate dressings

Bonomo, Pierluigi; Desideri, Isacco; Loi, Mauro; Ciccone, L.P.; Russo, Monica Lo; Becherini, Carlotta; Greto, Daniela; Simontacchi, Gabriele; Pimpinelli, Nicola; Livi, Lorenzo

doi:10.1007/s00520-018-4606-2

Cited by 15 publications

(14 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Standard supportive care measures (nutritional counseling, pain management, placement of central venous catheters for IV fluids) were routinely implemented. Our standardized policy for skin toxicity management was previously described . A CT scan (Big Bore, Philips Medical Systems, Cleveland, Ohio) was acquired at 3 mm slice width for radiation treatment planning.…”

Section: Methodsmentioning

confidence: 99%

Analysis of skin dose distribution for the prediction of severe radiation dermatitis in head and neck squamous cell carcinoma patients treated with concurrent chemo‐radiotherapy

et al. 2019

Self Cite

View full text Add to dashboard Cite

Background: We investigated whether the pattern of intensity-modulated radiotherapy (IMRT) dose distribution to the skin can be correlated with the development of G3/G4 radiation dermatitis (RD). Methods: A frequency-matched cohort analysis was perfomed on patients treated with IMRT and concurrent cisplatin or cetuximab. Risk ratios were obtained by fitting Poisson regression models. Results: The incidence of G3/G4 RD was 41.1% in 90 patients included (50% vs 36.6% in the cetuximab and cisplatin cohorts, respectively). In multivariate analysis, PS ≥ 1 and weight loss at RT completion >10 kg were the only factors that retained significance. The best dosimetric predictive accuracy was provided by 19.9 cc and 5.8 cc of skin ring 2 mm V50 and V60, respectively (AUC: 0.61 for both). Conclusion: Along with clinical factors, the pattern of dose distribution to a ring structure localized 2 mm below the patient's surface may help predict the development of severe RD. K E Y W O R D Shead and neck cancer, intensity-modulated radiotherapy, predictive factors, radiation dermatitis, squamous cell carcinoma

show abstract

Section: Methodsmentioning

confidence: 99%

Analysis of skin dose distribution for the prediction of severe radiation dermatitis in head and neck squamous cell carcinoma patients treated with concurrent chemo‐radiotherapy

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…At the same time, there was no difference between the control group using institution routine, aqueous cream, mild soap, water thermal gel, placebo, and no intervention [30]. Regarding bio-radiation dermatitis, Bonomo et al confirmed the effectiveness of calcium dressing for moist exfoliation [22]. Side effects like radiodermatitis which is particularly visible may significantly impair the quality of life.…”

Section: Prevention and Treatmentmentioning

confidence: 99%

“…CTCAE 4.0 appears to be the most commonly used scale during clinical assessment, but it is not a unified, unambiguous system for the assessment of post-radiation reactions [19]. It is worth mentioning that the combined treatment involving concomitant radiotherapy and EGFR inhibitor may result in reaction called bio-radiation dermatitis [22]. This type of reaction has a different pathogenesis and clinical characteristics [14].…”

Section: Clinical Classificationmentioning

confidence: 99%

What is new when it comes to acute and chronic radiation-induced dermatitis in head and neck cancer patients?

Dudek

Rutkowski

Kamińska‐Winciorek

et al. 2020

Nowotwory. Journal of Oncology

View full text Add to dashboard Cite

Head and neck cancer is a serious clinical and social problem. Surgery and radiotherapy play the most important role in treatment and give the chance of cure. Optimal treatment of patients with head and neck cancer should provide for the maximum destruction of cancerous tissue, saving as much healthy tissue as possible. Despite this, due to radiotherapy still almost 90% of patients develop skin symptoms. It seems that the mechanism of radiodermatitis is quite clear, but studies assume that its pathogenesis is not fully understood and there is much to be clarified. Acute and chronic dermatitis caused by radiotherapy is usually diagnosed according to clinical criteria. It seems that it would be useful to have a photographic classification that would facilitate and unify the clinical evaluation. In this article we shall summarize the current knowledge about the mechanisms of formation, risk factors, clinical classifications and methods for the prevention and treatment of acute and chronic radiation dermatitis. We have included clinical photos that depict individual stages according to the clinical classification of RTOG.

show abstract

“…It can be associated with xerosis, itch and involves face, trunk, and may extend to extremities. Its severity is dose‐dependent, indirectly predictive of therapeutic response 6 …”

Section: Figurementioning

confidence: 99%

Radiation recall during cemiplimab therapy for locally advanced cutaneous squamous cell carcinoma

Vaccaro

Bertino

Santarpía

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

Management of severe bio-radiation dermatitis induced by radiotherapy and cetuximab in patients with head and neck cancer: emphasizing the role of calcium alginate dressings

Cited by 15 publications

References 29 publications

Analysis of skin dose distribution for the prediction of severe radiation dermatitis in head and neck squamous cell carcinoma patients treated with concurrent chemo‐radiotherapy

Analysis of skin dose distribution for the prediction of severe radiation dermatitis in head and neck squamous cell carcinoma patients treated with concurrent chemo‐radiotherapy

What is new when it comes to acute and chronic radiation-induced dermatitis in head and neck cancer patients?

Radiation recall during cemiplimab therapy for locally advanced cutaneous squamous cell carcinoma

Contact Info

Product

Resources

About